These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Suppressive effects of levetiracetam on neuroinflammation and phagocytic microglia: A comparative study of levetiracetam, valproate and carbamazepine. Itoh K; Taniguchi R; Matsuo T; Oguro A; Vogel CFA; Yamazaki T; Ishihara Y Neurosci Lett; 2019 Aug; 708():134363. PubMed ID: 31276728 [TBL] [Abstract][Full Text] [Related]
4. AMPA receptor antagonist perampanel affects glioblastoma cell growth and glutamate release in vitro. Lange F; Weßlau K; Porath K; Hörnschemeyer MF; Bergner C; Krause BJ; Mullins CS; Linnebacher M; Köhling R; Kirschstein T PLoS One; 2019; 14(2):e0211644. PubMed ID: 30716120 [TBL] [Abstract][Full Text] [Related]
5. Efficacy of levetiracetam for reducing rolandic discharges in comparison with carbamazepine and valproate sodium in rolandic epilepsy. Kanemura H; Sano F; Ohyama T; Aihara M Seizure; 2018 Nov; 62():79-83. PubMed ID: 30308427 [TBL] [Abstract][Full Text] [Related]
6. The effects of levetiracetam, carbamazepine, and sodium valproate on P100 and P300 in epileptic patients. Tumay Y; Altun Y; Ekmekci K; Ozkul Y Clin Neuropharmacol; 2013; 36(2):55-8. PubMed ID: 23503548 [TBL] [Abstract][Full Text] [Related]
8. KOMET: an unblinded, randomised, two parallel-group, stratified trial comparing the effectiveness of levetiracetam with controlled-release carbamazepine and extended-release sodium valproate as monotherapy in patients with newly diagnosed epilepsy. Trinka E; Marson AG; Van Paesschen W; Kälviäinen R; Marovac J; Duncan B; Buyle S; Hallström Y; Hon P; Muscas GC; Newton M; Meencke HJ; Smith PE; Pohlmann-Eden B; J Neurol Neurosurg Psychiatry; 2013 Oct; 84(10):1138-47. PubMed ID: 22933814 [TBL] [Abstract][Full Text] [Related]
9. Comparative effectiveness of levetiracetam, valproate and carbamazepine among elderly patients with newly diagnosed epilepsy: subgroup analysis of the randomized, unblinded KOMET study. Pohlmann-Eden B; Marson AG; Noack-Rink M; Ramirez F; Tofighy A; Werhahn KJ; Wild I; Trinka E BMC Neurol; 2016 Aug; 16(1):149. PubMed ID: 27552848 [TBL] [Abstract][Full Text] [Related]
10. Preliminary evidence about irritability in patients with epilepsy treated by perampanel as first add-on therapy compared to levetiracetam and valproic acid. Liguori C; Turner K; Izzi F; Assogna M; Canevini MP; Mercuri NB; Placidi F CNS Neurosci Ther; 2019 May; 25(5):632-637. PubMed ID: 30675751 [TBL] [Abstract][Full Text] [Related]
11. Experience of Low Dose Perampanel to Add-on in Glioma Patients with Levetiracetam-uncontrollable Epilepsy. Chonan M; Saito R; Kanamori M; Osawa SI; Watanabe M; Suzuki H; Nakasato N; Tominaga T Neurol Med Chir (Tokyo); 2020 Jan; 60(1):37-44. PubMed ID: 31748440 [TBL] [Abstract][Full Text] [Related]
12. Valproic acid affected the survival and invasiveness of human glioma cells through diverse mechanisms. Chen Y; Tsai YH; Tseng SH J Neurooncol; 2012 Aug; 109(1):23-33. PubMed ID: 22528797 [TBL] [Abstract][Full Text] [Related]
13. Long-lasting antiepileptic effects of levetiracetam against epileptic seizures in the spontaneously epileptic rat (SER): differentiation of levetiracetam from conventional antiepileptic drugs. Ji-qun C; Ishihara K; Nagayama T; Serikawa T; Sasa M Epilepsia; 2005 Sep; 46(9):1362-70. PubMed ID: 16146430 [TBL] [Abstract][Full Text] [Related]
14. Combination of levetiracetam and IFN-α increased temozolomide efficacy in MGMT-positive glioma. Ni XR; Guo CC; Yu YJ; Yu ZH; Cai HP; Wu WC; Ma JX; Chen FR; Wang J; Chen ZP Cancer Chemother Pharmacol; 2020 Dec; 86(6):773-782. PubMed ID: 33074386 [TBL] [Abstract][Full Text] [Related]
15. Different effects of valproic acid on proliferation and migration of malignant glioma cells in vitro. Knüpfer MM; Pulzer F; Schindler I; Hernaíz Driever P; Knüpfer H; Keller E Anticancer Res; 2001; 21(1A):347-51. PubMed ID: 11299760 [TBL] [Abstract][Full Text] [Related]
16. Measurement of levetiracetam drug levels to assist with seizure control and monitoring of drug interactions with other anti-epileptic medications (AEMs). Stepanova D; Beran RG Seizure; 2014 May; 23(5):371-6. PubMed ID: 24630809 [TBL] [Abstract][Full Text] [Related]
17. Cellular Effects of the Antiepileptic Drug Valproic Acid in Glioblastoma. Eckert M; Klumpp L; Huber SM Cell Physiol Biochem; 2017; 44(4):1591-1605. PubMed ID: 29212069 [TBL] [Abstract][Full Text] [Related]
18. Efficacy and tolerability of anti-epileptic drugs-an internet study. Wieshmann UC; Baker G Acta Neurol Scand; 2017 May; 135(5):533-539. PubMed ID: 27757951 [TBL] [Abstract][Full Text] [Related]
19. Effects of treatment with clinically relevant valproate, carbamazepine, oxcarbazepine, topiramate, lamotrigine and levetiracetam on ovarian folliculogenesis in young rats. Cansu A; Gurgen SG; Demirhan YN; Ozkan Kart P; Yildirim M; Alver A; Yeni Lmez E; Sönmez FM Epilepsy Res; 2022 Aug; 184():106966. PubMed ID: 35763982 [TBL] [Abstract][Full Text] [Related]
20. Synergistic Effect of Perampanel and Temozolomide in Human Glioma Cell Lines. Salmaggi A; Corno C; Maschio M; Donzelli S; D'Urso A; Perego P; Ciusani E J Pers Med; 2021 May; 11(5):. PubMed ID: 34068749 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]